Type 2 diabetes, prediabetes, and MASLD: who and when to screen and how to treat? [0.03%]
2型糖尿病、糖尿病前期和MASLD：如何筛查及治疗？
Christopher D Byrne,Giovanni Targher,Ryan M Buchanan
Christopher D Byrne
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches [0.03%]
从患者角度重新评估2型糖尿病缓解的概念
Kamlesh Khunti,Dimitris Papamargaritis,Vanita R Aroda et al.
Kamlesh Khunti et al.
Controlling weight and cardiovascular risk factors is paramount in type 2 diabetes management; however, the definition and feasibility of remission warrant closer examination. Type 2 diabetes remission, typically attained through weight los...
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice [0.03%]
多发性内分泌腺瘤病1型(MEN1)最佳诊疗实践的建议和指南
Maria Luisa Brandi,Carolina R C Pieterman,Katherine A English et al.
Maria Luisa Brandi et al.
Multiple endocrine neoplasia type 1 (MEN1) is characterised by combined occurrence of parathyroid tumours, duodenopancreatic neuroendocrine tumours, and anterior pituitary adenomas. Some patients might also develop thymic and bronchopulmona...
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis [0.03%]
神经内分泌肿瘤的治疗方法：三项系统评价和一项荟萃分析
Katherine A English,Carolina R C Pieterman,Francesca Marini et al.
Katherine A English et al.
Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disorder characterised by the combined occurrence of parathyroid, pancreatic, and pituitary tumours. Current treatments are based on very low-qua...
IcoSema and the evolution of fixed-ratio insulin-GLP-1 receptor agonist therapies [0.03%]
ICOSEMA及固定比率胰岛素-GLP-1受体激动剂疗法的演变
Guillermo Umpierrez,Thaer Idrees
Guillermo Umpierrez
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial [0.03%]
一周一次IcoSema与一周一次胰岛素icodec治疗2型糖尿病的比较：一项开放性、多中心、以目标为导向的随机IIIa期试验（COMBINE 1）
Chantal Mathieu,Francesco Giorgino,Sin Gon Kim et al.
Chantal Mathieu et al.
Background: IcoSema is a once‑weekly combination therapy of basal insulin icodec (icodec) and semaglutide (a GLP‑1 analogue) currently in development. COMBINE 1 compared the efficacy and safety of IcoSema with once‑wee...
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial [0.03%]
一周一次的IcoSema与多次皮下注射胰岛素治疗2型糖尿病的比较（COMBINE 3）：一项开放标签、多中心、以目标值指导治疗的非劣效性、随机三期临床试验
Liana K Billings,Francesco Andreozzi,Marie Frederiksen et al.
Liana K Billings et al.
Background: IcoSema is a once-weekly combination therapy of basal insulin icodec (icodec) and semaglutide (a GLP-1 analogue) developed for the treatment of type 2 diabetes. We aimed to evaluate the efficacy and safety of ...
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology